A presentation at the Radiological Society of North America 2018 Annual Meeting describing the results of a study investigating the potential role of functional OA/US imaging-derived hemoglobin de-oxygenation and angiogenesis feature scoring combined with conventional gray-scale US in non-invasively diagnosing breast cancer molecular subtypes.7 The data demonstrate that functional OA/US features provide a non-invasive approach to helping distinguish breast cancer molecular subtypes. The study authors conclude that data from such subtype analyses may help facilitate clinical management decisions.

A publication in ClinicoEconomics and Outcomes Research that found the annual U.S. cost of false-positive breast biopsies exceeds $2 billion.8 The study also found that nearly $8 billion is spent annually on follow-up breast diagnostic procedures (mammograms, ultrasound and biopsies). The study authors emphasized the need for highly effective tools that can exclude patients whose suspicious breast masses are benign before they are subjected to invasive diagnostic procedures.


A publication in the American Journal of Roentgenology describing a novel advanced statistical method for downgrading the risk classification of breast masses to reduce the need for unnecessary breast biopsies.9 This method, the NLR, can be used with diagnostic imaging output to downgrade breast mass risk classification. The use of the NLR along with BI-RADS 4 subcategories can help to reduce the number of false-positives without experiencing excessive negative results that would lead to cancer going undiagnosed.


About Seno Medical Instruments, Inc.
Seno Medical Instruments, Inc. is a San Antonio, Texas-based medical imaging company committed to the development and commercialization of a new modality in cancer diagnosis: opto-acoustic imaging. Seno Medical's Imagio® Breast Imaging System fuses opto-acoustic technology with ultrasound (OA/US) to generate fused real-time functional and anatomical images of the breast. The opto-acoustic images provide a unique blood map around breast masses while the ultrasound provides a traditional anatomic image. Through the appearance or absence of two hallmark indicators of cancer – angiogenesis and deoxygenation – Seno Medical believes that the Imagio OA/US breast imaging system will be a more effective tool to help radiologists confirm or rule out malignancy than current diagnostic imaging modalities – without exposing patients to potentially harmful ionizing radiation (x-rays) or contrast agents. To learn more about Seno Medical's OA/US imaging technology and applications, visit www.SenoMedical.com.

Back to HCB News

Women's Health Homepage